These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

136 related items for PubMed ID: 11448904

  • 1. Phase I and pharmacological study of the oral matrix metalloproteinase inhibitor, MMI270 (CGS27023A), in patients with advanced solid cancer.
    Levitt NC, Eskens FA, O'Byrne KJ, Propper DJ, Denis LJ, Owen SJ, Choi L, Foekens JA, Wilner S, Wood JM, Nakajima M, Talbot DC, Steward WP, Harris AL, Verweij J.
    Clin Cancer Res; 2001 Jul; 7(7):1912-22. PubMed ID: 11448904
    [Abstract] [Full Text] [Related]

  • 2. A dose-finding and pharmacokinetic study of the matrix metalloproteinase inhibitor MMI270 (previously termed CGS27023A) with 5-FU and folinic acid.
    Eatock M, Cassidy J, Johnson J, Morrison R, Devlin M, Blackey R, Owen S, Choi L, Twelves C.
    Cancer Chemother Pharmacol; 2005 Jan; 55(1):39-46. PubMed ID: 15368080
    [Abstract] [Full Text] [Related]

  • 3. A phase I and pharmacokinetic study of Col-3 (Metastat), an oral tetracycline derivative with potent matrix metalloproteinase and antitumor properties.
    Syed S, Takimoto C, Hidalgo M, Rizzo J, Kuhn JG, Hammond LA, Schwartz G, Tolcher A, Patnaik A, Eckhardt SG, Rowinsky EK.
    Clin Cancer Res; 2004 Oct 01; 10(19):6512-21. PubMed ID: 15475438
    [Abstract] [Full Text] [Related]

  • 4. Phase I dose escalation study of telatinib, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor 2 and 3, platelet-derived growth factor receptor beta, and c-Kit, in patients with advanced or metastatic solid tumors.
    Eskens FA, Steeghs N, Verweij J, Bloem JL, Christensen O, van Doorn L, Ouwerkerk J, de Jonge MJ, Nortier JW, Kraetzschmar J, Rajagopalan P, Gelderblom H.
    J Clin Oncol; 2009 Sep 01; 27(25):4169-76. PubMed ID: 19636022
    [Abstract] [Full Text] [Related]

  • 5. A phase II trial of marimastat in advanced pancreatic cancer.
    Evans JD, Stark A, Johnson CD, Daniel F, Carmichael J, Buckels J, Imrie CW, Brown P, Neoptolemos JP.
    Br J Cancer; 2001 Dec 14; 85(12):1865-70. PubMed ID: 11747327
    [Abstract] [Full Text] [Related]

  • 6. A phase I and pharmacologic study of the matrix metalloproteinase inhibitor CP-471,358 in patients with advanced solid tumors.
    Planting A, van der Gaast A, Schöffski P, Bartkowski M, Verheij C, Noe D, Ferrante K, Verweij J.
    Cancer Chemother Pharmacol; 2005 Feb 14; 55(2):136-42. PubMed ID: 15592721
    [Abstract] [Full Text] [Related]

  • 7. Effect of food on the pharmacokinetics of oral MMI270B (CGS 27023A), a novel matrix metalloproteinase inhibitor.
    Eskens FA, Levitt NC, Sparreboom A, Choi L, Mather R, Verweij J, Harris AL.
    Clin Cancer Res; 2000 Feb 14; 6(2):431-3. PubMed ID: 10690520
    [Abstract] [Full Text] [Related]

  • 8. Safety, pharmacokinetics, and efficacy of AMG 706, an oral multikinase inhibitor, in patients with advanced solid tumors.
    Rosen LS, Kurzrock R, Mulay M, Van Vugt A, Purdom M, Ng C, Silverman J, Koutsoukos A, Sun YN, Bass MB, Xu RY, Polverino A, Wiezorek JS, Chang DD, Benjamin R, Herbst RS.
    J Clin Oncol; 2007 Jun 10; 25(17):2369-76. PubMed ID: 17557949
    [Abstract] [Full Text] [Related]

  • 9. Phase I study to determine the safety and pharmacokinetics of oral administration of TAS-102 in patients with solid tumors.
    Hong DS, Abbruzzese JL, Bogaard K, Lassere Y, Fukushima M, Mita A, Kuwata K, Hoff PM.
    Cancer; 2006 Sep 15; 107(6):1383-90. PubMed ID: 16902987
    [Abstract] [Full Text] [Related]

  • 10. A phase I and pharmacological study of the matrix metalloproteinase inhibitor BB-3644 in patients with solid tumours.
    Wall L, Talbot DC, Bradbury P, Jodrell DI.
    Br J Cancer; 2004 Feb 23; 90(4):800-4. PubMed ID: 14970856
    [Abstract] [Full Text] [Related]

  • 11. A phase I pharmacokinetic and pharmacodynamic study of s-3304, a novel matrix metalloproteinase inhibitor, in patients with advanced and refractory solid tumors.
    Chiappori AA, Eckhardt SG, Bukowski R, Sullivan DM, Ikeda M, Yano Y, Yamada-Sawada T, Kambayashi Y, Tanaka K, Javle MM, Mekhail T, O'bryant CL, Creaven PJ.
    Clin Cancer Res; 2007 Apr 01; 13(7):2091-9. PubMed ID: 17404091
    [Abstract] [Full Text] [Related]

  • 12. Phase I and pharmacologic study of PKI166, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies.
    Hoekstra R, Dumez H, Eskens FA, van der Gaast A, Planting AS, de Heus G, Sizer KC, Ravera C, Vaidyanathan S, Bucana C, Fidler IJ, van Oosterom AT, Verweij J.
    Clin Cancer Res; 2005 Oct 01; 11(19 Pt 1):6908-15. PubMed ID: 16203782
    [Abstract] [Full Text] [Related]

  • 13. Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer.
    Papandreou CN, Daliani DD, Nix D, Yang H, Madden T, Wang X, Pien CS, Millikan RE, Tu SM, Pagliaro L, Kim J, Adams J, Elliott P, Esseltine D, Petrusich A, Dieringer P, Perez C, Logothetis CJ.
    J Clin Oncol; 2004 Jun 01; 22(11):2108-21. PubMed ID: 15169797
    [Abstract] [Full Text] [Related]

  • 14. Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors.
    Murren J, Modiano M, Clairmont C, Lambert P, Savaraj N, Doyle T, Sznol M.
    Clin Cancer Res; 2003 Sep 15; 9(11):4092-100. PubMed ID: 14519631
    [Abstract] [Full Text] [Related]

  • 15. Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results.
    Rugo HS, Herbst RS, Liu G, Park JW, Kies MS, Steinfeldt HM, Pithavala YK, Reich SD, Freddo JL, Wilding G.
    J Clin Oncol; 2005 Aug 20; 23(24):5474-83. PubMed ID: 16027439
    [Abstract] [Full Text] [Related]

  • 16. Phase I clinical trial to determine maximum tolerated dose of oral albendazole in patients with advanced cancer.
    Pourgholami MH, Szwajcer M, Chin M, Liauw W, Seef J, Galettis P, Morris DL, Links M.
    Cancer Chemother Pharmacol; 2010 Feb 20; 65(3):597-605. PubMed ID: 19904538
    [Abstract] [Full Text] [Related]

  • 17. Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43-9006, in patients with advanced, refractory solid tumors.
    Clark JW, Eder JP, Ryan D, Lathia C, Lenz HJ.
    Clin Cancer Res; 2005 Aug 01; 11(15):5472-80. PubMed ID: 16061863
    [Abstract] [Full Text] [Related]

  • 18. Anti-tumor angiogenic effect of a matrix metalloproteinase inhibitor MMI270.
    Nakamura ES, Koizumi K, Yamaura T, Saiki I.
    Anticancer Res; 2003 Aug 01; 23(1A):411-7. PubMed ID: 12680241
    [Abstract] [Full Text] [Related]

  • 19. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers.
    Bergman AJ, Stevens C, Zhou Y, Yi B, Laethem M, De Smet M, Snyder K, Hilliard D, Tanaka W, Zeng W, Tanen M, Wang AQ, Chen L, Winchell G, Davies MJ, Ramael S, Wagner JA, Herman GA.
    Clin Ther; 2006 Jan 01; 28(1):55-72. PubMed ID: 16490580
    [Abstract] [Full Text] [Related]

  • 20. Phase I trial of pazopanib in patients with advanced cancer.
    Hurwitz HI, Dowlati A, Saini S, Savage S, Suttle AB, Gibson DM, Hodge JP, Merkle EM, Pandite L.
    Clin Cancer Res; 2009 Jun 15; 15(12):4220-7. PubMed ID: 19509175
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.